FendX Technologies (XCNQ:FNDX) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is FendX Technologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

FendX Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. FendX Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. FendX Technologies's annualized Revenue for the quarter that ended in Dec. 2023 was C$0.00 Mil.

FendX Technologies Debt-to-Revenue Historical Data

The historical data trend for FendX Technologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FendX Technologies Debt-to-Revenue Chart

FendX Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

FendX Technologies Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial				N/A	N/A	N/A	N/A	N/A

Competitive Comparison of FendX Technologies's Debt-to-Revenue

For the Specialty Chemicals subindustry, FendX Technologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FendX Technologies's Debt-to-Revenue Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, FendX Technologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where FendX Technologies's Debt-to-Revenue falls into.

FendX Technologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

FendX Technologies's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

FendX Technologies's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

FendX Technologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of FendX Technologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

FendX Technologies (XCNQ:FNDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » FendX Technologies Inc (XCNQ:FNDX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

FDXTF:USA E8D:Germany

Address

2010 Winston Park Drive, 2nd Floor, Oakville, ON, CAN, L6H 5R7

Website

https://www.fendxtech.com

FendX Technologies Inc is a technology company focused on developing surface protection products that protect surfaces from pathogen contamination. It is focused on the research, development and commercialization of surface protection coatings using Licensed Technology. The company is currently developing its anticipated first product, REPELWRAP to protect high-contact surfaces from contamination to reduce the transmission of harmful pathogens. The Company has a growing intellectual property portfolio consisting of licensed nonprovisional national stage patent applications.